Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension [0.03%]
长期使用药物阻断肾素血管紧张素系统对原发性高血压纤溶系统的影响
Kazuyuki Sakata,Roberts Pawlak,Tetumei Urano et al.
Kazuyuki Sakata et al.
To assess the effects of pharmacological interruption of the renin-angiotensin system on the fibrinolysis, tissue plasminogen activator antigen (t-PA), plasminogen activator inhibitor-1 antigens (PAI-1) and neurohormones, such as plasma ren...
Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients [0.03%]
555例接受每日一次低分子肝素（亭扎肝素）门诊治疗的深静脉血栓形成患者的家访治疗经验报告
Leif Lapidus,Jens Börretzen,Martin Fahlén et al.
Leif Lapidus et al.
During a 22-month period, 555 consecutive patients at seven hospitals in the western part of Sweden with an acute deep vein thrombosis (DVT) not involving the iliac vein and not having pulmonary embolism were included in a study testing the...
Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies [0.03%]
亚甲基四氢叶酸还原酶基因C677T多态性与静脉血栓栓塞发病风险的meta分析：来自31项研究的结果
J G Ray,D Shmorgun,W S Chan
J G Ray
Background: Although the common 677 C --> T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene is implicated in the development of hyperhomocysteinemia, its correlation with venous thromboembolism (VTE) ...
Elisabeth Erhardtsen
Elisabeth Erhardtsen
Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in haemophilia patients with inhibitors and has also been used successfully in non-haemophilia patients with acquired antibodies against FVIII (acquired haemophili...
The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients [0.03%]
重组活化因子VII在非血友病患者手术止血中的应用
Maadh Aldouri
Maadh Aldouri
Recombinant factor VIIa (rFVIIa, NovoSeven) is effective and appears safe in the management of bleeding episodes and provision of surgical cover in haemophilia patients with inhibitors. Additionally, rFVIIa has been considered as a universa...
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? [0.03%]
重组活化因子VIIa治疗血小板功能异常患者的出血有效性和安全性研究
Yves Laurian
Yves Laurian
The mechanism of action of recombinant factor VIIa (rFVIIa), i.e. increased thrombin generation on the membrane of activated platelets, as well as the results from in vitro and ex vivo models of thrombocytopenia or inherited thrombocytopath...
Ulla Hedner
Ulla Hedner
Haemophilia is the most serious bleeding model that nature has provided us with, indicating the importance of factor FVIII and FIX in haemostasis. According to current knowledge, haemostasis is initiated by the formation of a complex betwee...
Loretto Lacey
Loretto Lacey
A literature review of the economics of managing haemophilia patients with inhibitors was conducted. It showed that haemophilia with inhibitors places a burden on the healthcare system and on the patient. Use of rFVIIa compared to 'usual th...
Susan Schonfield,Keith Reid
Susan Schonfield
The Pan-Thames Haemophilia Consortium was established to provide coherent regional planning of haemophilia services. The Expert Advisory Group is a clinical reference point for the consortium and was established to consider specifically ele...
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors [0.03%]
用于具有高滴度抑制物的血友病儿童外科手术和急性出血发作的重组活化因子VII治疗
Owen P Smith
Owen P Smith
The development of inhibitors to therapeutic factor concentrates in children with haemophilia A or B is a troublesome complication of factor replacement therapy. Immune tolerance protocols have been developed to eliminate the inhibitors, an...